Evaluation of Psilocybin (TRP-8802) to Decrease Hyperphagia
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a single-center phase 2a open-label study to assess the efficacy and safety of a dose
of psilocybin in subjects with hyperphagia resulting in overeating during both dosing
sessions. Subjects will undergo screening, preparation therapy sessions, dosing, integration
therapy sessions, and follow-up for 24 weeks following the second of 2 doses. The total
participation in the study will be up to 7 months. The study will assess change from baseline
in body mass index (BMI). Safety will be assessed during dosing sessions and over a 24 week
follow-up period.